Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin

Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody–drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. F...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinert, Jochim, Beitzen-Heineke, Antonia, Wethmar, Klaus, Stelljes, Matthias, Fiedler, Walter, Schwartz, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510963/
https://www.ncbi.nlm.nih.gov/pubmed/34331563
http://dx.doi.org/10.1007/s00277-021-04601-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510963/
https://www.ncbi.nlm.nih.gov/pubmed/34331563
http://dx.doi.org/10.1007/s00277-021-04601-0

Ejemplares similares